Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study

PURPOSE: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure. METHODS: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with P...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yongkang, Fu, Shumin, Liu, Kan, Mao, Ye, Wu, Jianbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612499/
https://www.ncbi.nlm.nih.gov/pubmed/37899984
http://dx.doi.org/10.2147/TCRM.S420371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612499/
https://www.ncbi.nlm.nih.gov/pubmed/37899984
http://dx.doi.org/10.2147/TCRM.S420371

Ejemplares similares